What did @annieandabby actually say?
The short version: she has three unopened boxes of Wegovy 0.25mg sitting in her fridge because she's too scared to inject it, her pharmacy keeps auto-filling the prescription despite her telling her doctor she hasn't started, her copay is $3, and she tried the stomach once and it hurt. She ended the video without injecting. No medical claims, no dosing advice, just a very relatable anxiety spiral in front of a spinach bag.
This is not a video making bold health claims. It's a woman holding a syringe and saying "I can't do it." That matters for how we evaluate it, because the things worth checking here are the background details, not dramatic misinformation.
Does the science back this up?
Needle anxiety around GLP-1 injections is real, documented, and underreported as a barrier to treatment. She's not being dramatic. The 0.25mg starting dose of semaglutide (Wegovy) uses a 4mm needle, and while that sounds small, injection anxiety doesn't scale with needle length in a logical way for most people.
A 2022 study by Matza et al. in Obesity Science and Practice found that injection anxiety was a meaningful barrier to GLP-1 initiation and adherence, particularly in patients without prior self-injection experience. Numbing the site with ice or cold packs before injection is a commonly recommended technique in nursing and patient education literature, and there's no evidence it's harmful. Her spinach-bag ice pack is unorthodox but mechanistically sound. Cooling the skin blunts superficial nociceptor signaling. It works.
What did they get right?
Quite a bit, actually. The 0.25mg dose is the correct FDA-approved starting dose for Wegovy, used for the first four weeks to reduce GI side effects before titration. She correctly identified that these starter pens are harder to find, which has been widely reported. Pharmacy auto-fills continuing without confirmed patient use is a real and genuinely problematic issue in specialty medication management, not something she invented.
Her $3 copay figure is plausible. Novo Nordisk's savings program has offered copays as low as $0-$25 for eligible commercially insured patients, though coverage and eligibility vary. She didn't claim everyone gets this rate, and she explicitly acknowledged "a lot of people can't actually get these or get them covered." That caveat matters. It's the right thing to say.
What did they get wrong?
Nothing medically dangerous. The terminology is mangled throughout, "semi-glued tied" instead of semaglutide, "wagobi" instead of Wegovy, but that's phonetic transcription of a brand name, not a factual error. The bigger concern is the implied situation: she has multiple pens that have been in the fridge for an extended period and mentions something may have "leaked" on one box. Wegovy pens should be stored at 36-46 degrees Fahrenheit and are stable in the refrigerator until the expiration date. If a pen was exposed to leakage from another product or left out of the fridge, that's a drug integrity concern worth raising with a pharmacist, not just a visual quirk.
She did not make any false clinical claims, recommend a dose, or suggest compounded semaglutide is equivalent to brand-name Wegovy. No violations here.
What should you actually know?
If you're in the same situation, a few things are worth knowing. First, injection anxiety at the start of Wegovy is common enough that it gets its own section in patient education materials. You are not alone and you are not failing. Second, if your pharmacy is auto-filling a specialty medication you're not taking, you can and should contact both the pharmacy and your prescribing provider to pause fills. Unused pens are expensive for the system even if your copay is low, and drug waste is a real issue. Third, cold numbing before injection is a legitimate technique. A 2019 review in the Journal of Diabetes Science and Technology by Spollett et al. noted that injection site preparation techniques, including cooling, can improve comfort and tolerability for self-injecting patients. Finally, if needle phobia is genuinely preventing you from starting a prescribed medication, that's a clinical conversation worth having. Some patients do better with autoinjectors, different sites, or brief behavioral coaching. This is solvable.